HK Stock Market Move | ASCLETIS-B(01672) rose over 5% in early trading with GIC's shareholding ratio increasing to 7%. ASC30 US Phase II study has completed enrollment.

ASCLETIS-B(01672) rose more than 5% in early trading, as of the time of writing, it has risen by 4.04% to HK$15.45, with a turnover of HK$16.3476 million. In terms of news, information disclosed by the Hong Kong Stock Exchange shows that on May 7th, the Singapore government investment fund (GIC) increased its holding of 122,000 shares of common stock of Gilead Sciences, worth approximately HK$2.0267 million. After the increase, GIC's holding increased to 74.808 million shares, and its holding ratio rose to 7%. This increase reflects GIC's continued optimism about Gilead Sciences' innovative research and development capabilities, strategic execution, and long-term development prospects, as well as the continued attention of the international capital market to the innovative pipeline value of Gilead Sciences. It is worth noting that the 13-week Phase II study of ASC30 for the treatment of type 2 diabetes in the United States has completed enrollment, and is expected to receive top-line data of the Phase II study for the treatment of type 2 diabetes in the third quarter of 2026. In the industry's view, ASC30 has superior weight loss data, good safety profile, and its molecular patent has been granted in the United States, with great potential in the field of diabetes treatment.